#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=The invention further provides antibodies, preferably monoclonal antibodies, which specifically bind to the polypeptides of the invention.
1-1	0-3	The	_	_	
1-2	4-13	invention	_	_	
1-3	14-21	further	_	_	
1-4	22-30	provides	_	_	
1-5	31-41	antibodies	_	_	
1-6	41-42	,	_	_	
1-7	43-53	preferably	_	_	
1-8	54-64	monoclonal	_	_	
1-9	65-75	antibodies	_	_	
1-10	75-76	,	_	_	
1-11	77-82	which	_	_	
1-12	83-95	specifically	_	_	
1-13	96-100	bind	_	_	
1-14	101-103	to	_	_	
1-15	104-107	the	_	_	
1-16	108-120	polypeptides	_	_	
1-17	121-123	of	_	_	
1-18	124-127	the	_	_	
1-19	128-137	invention	_	_	
1-20	137-138	.	_	_	

#Text=Methods are also provided for producing antibodies in a host animal.
2-1	139-146	Methods	_	_	
2-2	147-150	are	_	_	
2-3	151-155	also	_	_	
2-4	156-164	provided	_	_	
2-5	165-168	for	_	_	
2-6	169-178	producing	_	_	
2-7	179-189	antibodies	_	_	
2-8	190-192	in	_	_	
2-9	193-194	a	_	_	
2-10	195-199	host	_	_	
2-11	200-206	animal	_	_	
2-12	206-207	.	_	_	

#Text=The methods of the invention comprise immunizing an animal with at least one K. pneumoniae-derived immunogenic component, wherein the immunogenic component comprises one or more of the polypeptides encoded by any one of SEQ ID NO: 1-SEQ ID NO: 7171 or sequence-conservative or function-conservative variants thereof; or polypeptides that are contained within any ORFs, including complete protein-coding sequences, of which any of SEQ ID NO: 1-SEQ ID NO: 7171 forms a part; or polypeptide sequences contained within any of SEQ ID NO: 7172-SEQ ID NO: 14342; or polypeptides of which any of SEQ ID NO: 7172-SEQ ID NO: 14342 forms a part.
3-1	208-211	The	_	_	
3-2	212-219	methods	_	_	
3-3	220-222	of	_	_	
3-4	223-226	the	_	_	
3-5	227-236	invention	_	_	
3-6	237-245	comprise	_	_	
3-7	246-256	immunizing	_	_	
3-8	257-259	an	_	_	
3-9	260-266	animal	_	_	
3-10	267-271	with	_	_	
3-11	272-274	at	_	_	
3-12	275-280	least	_	_	
3-13	281-284	one	_	_	
3-14	285-286	K	_	_	
3-15	286-287	.	_	_	
3-16	288-306	pneumoniae-derived	_	_	
3-17	307-318	immunogenic	_	_	
3-18	319-328	component	_	_	
3-19	328-329	,	_	_	
3-20	330-337	wherein	_	_	
3-21	338-341	the	_	_	
3-22	342-353	immunogenic	_	_	
3-23	354-363	component	_	_	
3-24	364-373	comprises	_	_	
3-25	374-377	one	_	_	
3-26	378-380	or	_	_	
3-27	381-385	more	_	_	
3-28	386-388	of	_	_	
3-29	389-392	the	_	_	
3-30	393-405	polypeptides	_	_	
3-31	406-413	encoded	_	_	
3-32	414-416	by	_	_	
3-33	417-420	any	_	_	
3-34	421-424	one	_	_	
3-35	425-427	of	_	_	
3-36	428-431	SEQ	_	_	
3-37	432-434	ID	_	_	
3-38	435-437	NO	_	_	
3-39	437-438	:	_	_	
3-40	439-440	1	_	_	
3-41	440-441	-	_	_	
3-42	441-444	SEQ	_	_	
3-43	445-447	ID	_	_	
3-44	448-450	NO	_	_	
3-45	450-451	:	_	_	
3-46	452-456	7171	_	_	
3-47	457-459	or	_	_	
3-48	460-481	sequence-conservative	_	_	
3-49	482-484	or	_	_	
3-50	485-506	function-conservative	_	_	
3-51	507-515	variants	_	_	
3-52	516-523	thereof	_	_	
3-53	523-524	;	_	_	
3-54	525-527	or	_	_	
3-55	528-540	polypeptides	_	_	
3-56	541-545	that	_	_	
3-57	546-549	are	_	_	
3-58	550-559	contained	_	_	
3-59	560-566	within	_	_	
3-60	567-570	any	_	_	
3-61	571-575	ORFs	_	_	
3-62	575-576	,	_	_	
3-63	577-586	including	_	_	
3-64	587-595	complete	_	_	
3-65	596-610	protein-coding	_	_	
3-66	611-620	sequences	_	_	
3-67	620-621	,	_	_	
3-68	622-624	of	_	_	
3-69	625-630	which	_	_	
3-70	631-634	any	_	_	
3-71	635-637	of	_	_	
3-72	638-641	SEQ	_	_	
3-73	642-644	ID	_	_	
3-74	645-647	NO	_	_	
3-75	647-648	:	_	_	
3-76	649-650	1	_	_	
3-77	650-651	-	_	_	
3-78	651-654	SEQ	_	_	
3-79	655-657	ID	_	_	
3-80	658-660	NO	_	_	
3-81	660-661	:	_	_	
3-82	662-666	7171	_	_	
3-83	667-672	forms	_	_	
3-84	673-674	a	_	_	
3-85	675-679	part	_	_	
3-86	679-680	;	_	_	
3-87	681-683	or	_	_	
3-88	684-695	polypeptide	_	_	
3-89	696-705	sequences	_	_	
3-90	706-715	contained	_	_	
3-91	716-722	within	_	_	
3-92	723-726	any	_	_	
3-93	727-729	of	_	_	
3-94	730-733	SEQ	_	_	
3-95	734-736	ID	_	_	
3-96	737-739	NO	_	_	
3-97	739-740	:	_	_	
3-98	741-745	7172	_	_	
3-99	745-746	-	_	_	
3-100	746-749	SEQ	_	_	
3-101	750-752	ID	_	_	
3-102	753-755	NO	_	_	
3-103	755-756	:	_	_	
3-104	757-762	14342	_	_	
3-105	762-763	;	_	_	
3-106	764-766	or	_	_	
3-107	767-779	polypeptides	_	_	
3-108	780-782	of	_	_	
3-109	783-788	which	_	_	
3-110	789-792	any	_	_	
3-111	793-795	of	_	_	
3-112	796-799	SEQ	_	_	
3-113	800-802	ID	_	_	
3-114	803-805	NO	_	_	
3-115	805-806	:	_	_	
3-116	807-811	7172	_	_	
3-117	811-812	-	_	_	
3-118	812-815	SEQ	_	_	
3-119	816-818	ID	_	_	
3-120	819-821	NO	_	_	
3-121	821-822	:	_	_	
3-122	823-828	14342	_	_	
3-123	829-834	forms	_	_	
3-124	835-836	a	_	_	
3-125	837-841	part	_	_	
3-126	841-842	.	_	_	

#Text=Host animals include any warm blooded animal, including without limitation mammals and birds.
4-1	843-847	Host	_	_	
4-2	848-855	animals	_	_	
4-3	856-863	include	_	_	
4-4	864-867	any	_	_	
4-5	868-872	warm	_	_	
4-6	873-880	blooded	_	_	
4-7	881-887	animal	_	_	
4-8	887-888	,	_	_	
4-9	889-898	including	_	_	
4-10	899-906	without	_	_	
4-11	907-917	limitation	_	_	
4-12	918-925	mammals	_	_	
4-13	926-929	and	_	_	
4-14	930-935	birds	_	_	
4-15	935-936	.	_	_	

#Text=Such antibodies have utility as reagents for immunoassays to evaluate the abundance and distribution of K. pneumoniae-specific antigens.
5-1	937-941	Such	_	_	
5-2	942-952	antibodies	_	_	
5-3	953-957	have	_	_	
5-4	958-965	utility	_	_	
5-5	966-968	as	_	_	
5-6	969-977	reagents	_	_	
5-7	978-981	for	_	_	
5-8	982-994	immunoassays	_	_	
5-9	995-997	to	_	_	
5-10	998-1006	evaluate	_	_	
5-11	1007-1010	the	_	_	
5-12	1011-1020	abundance	_	_	
5-13	1021-1024	and	_	_	
5-14	1025-1037	distribution	_	_	
5-15	1038-1040	of	_	_	
5-16	1041-1042	K	_	_	
5-17	1042-1043	.	_	_	
5-18	1044-1063	pneumoniae-specific	_	_	
5-19	1064-1072	antigens	_	_	
5-20	1072-1073	.	_	_	

#Text=In yet another aspect, the invention provides diagnostic methods for detecting K. pneumoniae antigenic components or anti-K. pneumoniae antibodies in a sample.
6-1	1074-1076	In	_	_	
6-2	1077-1080	yet	_	_	
6-3	1081-1088	another	_	_	
6-4	1089-1095	aspect	_	_	
6-5	1095-1096	,	_	_	
6-6	1097-1100	the	_	_	
6-7	1101-1110	invention	_	_	
6-8	1111-1119	provides	_	_	
6-9	1120-1130	diagnostic	_	_	
6-10	1131-1138	methods	_	_	
6-11	1139-1142	for	_	_	
6-12	1143-1152	detecting	_	_	
6-13	1153-1154	K	_	_	
6-14	1154-1155	.	_	_	
6-15	1156-1166	pneumoniae	_	_	
6-16	1167-1176	antigenic	_	_	
6-17	1177-1187	components	_	_	
6-18	1188-1190	or	_	_	
6-19	1191-1197	anti-K	_	_	
6-20	1197-1198	.	_	_	
6-21	1199-1209	pneumoniae	_	_	
6-22	1210-1220	antibodies	_	_	
6-23	1221-1223	in	_	_	
6-24	1224-1225	a	_	_	
6-25	1226-1232	sample	_	_	
6-26	1232-1233	.	_	_	

#Text=K. pneumoniae antigenic components may be detected by known processes, including but not limited to detection by a process comprising: (i) contacting a sample suspected to contain a bacterial antigenic component with a bacterial-specific antibody, under conditions in which a stable antigen-antibody complex can form between the antibody and bacterial antigenic components in the sample; and (ii) detecting any antigen-antibody complex formed in step (i), wherein detection of an antigen-antibody complex indicates the presence of at least one bacterial antigenic component in the sample.
7-1	1234-1235	K	_	_	
7-2	1235-1236	.	_	_	
7-3	1237-1247	pneumoniae	_	_	
7-4	1248-1257	antigenic	_	_	
7-5	1258-1268	components	_	_	
7-6	1269-1272	may	_	_	
7-7	1273-1275	be	_	_	
7-8	1276-1284	detected	_	_	
7-9	1285-1287	by	_	_	
7-10	1288-1293	known	_	_	
7-11	1294-1303	processes	_	_	
7-12	1303-1304	,	_	_	
7-13	1305-1314	including	_	_	
7-14	1315-1318	but	_	_	
7-15	1319-1322	not	_	_	
7-16	1323-1330	limited	_	_	
7-17	1331-1333	to	_	_	
7-18	1334-1343	detection	_	_	
7-19	1344-1346	by	_	_	
7-20	1347-1348	a	_	_	
7-21	1349-1356	process	_	_	
7-22	1357-1367	comprising	_	_	
7-23	1367-1368	:	_	_	
7-24	1369-1370	(	_	_	
7-25	1370-1371	i	_	_	
7-26	1371-1372	)	_	_	
7-27	1373-1383	contacting	_	_	
7-28	1384-1385	a	_	_	
7-29	1386-1392	sample	_	_	
7-30	1393-1402	suspected	_	_	
7-31	1403-1405	to	_	_	
7-32	1406-1413	contain	_	_	
7-33	1414-1415	a	_	_	
7-34	1416-1425	bacterial	_	_	
7-35	1426-1435	antigenic	_	_	
7-36	1436-1445	component	_	_	
7-37	1446-1450	with	_	_	
7-38	1451-1452	a	_	_	
7-39	1453-1471	bacterial-specific	_	_	
7-40	1472-1480	antibody	_	_	
7-41	1480-1481	,	_	_	
7-42	1482-1487	under	_	_	
7-43	1488-1498	conditions	_	_	
7-44	1499-1501	in	_	_	
7-45	1502-1507	which	_	_	
7-46	1508-1509	a	_	_	
7-47	1510-1516	stable	_	_	
7-48	1517-1533	antigen-antibody	_	_	
7-49	1534-1541	complex	_	_	
7-50	1542-1545	can	_	_	
7-51	1546-1550	form	_	_	
7-52	1551-1558	between	_	_	
7-53	1559-1562	the	_	_	
7-54	1563-1571	antibody	_	_	
7-55	1572-1575	and	_	_	
7-56	1576-1585	bacterial	_	_	
7-57	1586-1595	antigenic	_	_	
7-58	1596-1606	components	_	_	
7-59	1607-1609	in	_	_	
7-60	1610-1613	the	_	_	
7-61	1614-1620	sample	_	_	
7-62	1620-1621	;	_	_	
7-63	1622-1625	and	_	_	
7-64	1626-1627	(	_	_	
7-65	1627-1629	ii	_	_	
7-66	1629-1630	)	_	_	
7-67	1631-1640	detecting	_	_	
7-68	1641-1644	any	_	_	
7-69	1645-1661	antigen-antibody	_	_	
7-70	1662-1669	complex	_	_	
7-71	1670-1676	formed	_	_	
7-72	1677-1679	in	_	_	
7-73	1680-1684	step	_	_	
7-74	1685-1686	(	_	_	
7-75	1686-1687	i	_	_	
7-76	1687-1688	)	_	_	
7-77	1688-1689	,	_	_	
7-78	1690-1697	wherein	_	_	
7-79	1698-1707	detection	_	_	
7-80	1708-1710	of	_	_	
7-81	1711-1713	an	_	_	
7-82	1714-1730	antigen-antibody	_	_	
7-83	1731-1738	complex	_	_	
7-84	1739-1748	indicates	_	_	
7-85	1749-1752	the	_	_	
7-86	1753-1761	presence	_	_	
7-87	1762-1764	of	_	_	
7-88	1765-1767	at	_	_	
7-89	1768-1773	least	_	_	
7-90	1774-1777	one	_	_	
7-91	1778-1787	bacterial	_	_	
7-92	1788-1797	antigenic	_	_	
7-93	1798-1807	component	_	_	
7-94	1808-1810	in	_	_	
7-95	1811-1814	the	_	_	
7-96	1815-1821	sample	_	_	
7-97	1821-1822	.	_	_	

#Text=In different embodiments of this method, the antibodies used are directed against a sequence encoded by any of SEQ ID NO: 1-SEQ ID NO: 7171 or sequence-conservative or function-conservative variants thereof, or against a polypeptide sequence contained in any of SEQ ID NO: 7172-SEQ ID NO: 14342 or function-conservative variants thereof.
8-1	1823-1825	In	_	_	
8-2	1826-1835	different	_	_	
8-3	1836-1847	embodiments	_	_	
8-4	1848-1850	of	_	_	
8-5	1851-1855	this	_	_	
8-6	1856-1862	method	_	_	
8-7	1862-1863	,	_	_	
8-8	1864-1867	the	_	_	
8-9	1868-1878	antibodies	_	_	
8-10	1879-1883	used	_	_	
8-11	1884-1887	are	_	_	
8-12	1888-1896	directed	_	_	
8-13	1897-1904	against	_	_	
8-14	1905-1906	a	_	_	
8-15	1907-1915	sequence	_	_	
8-16	1916-1923	encoded	_	_	
8-17	1924-1926	by	_	_	
8-18	1927-1930	any	_	_	
8-19	1931-1933	of	_	_	
8-20	1934-1937	SEQ	_	_	
8-21	1938-1940	ID	_	_	
8-22	1941-1943	NO	_	_	
8-23	1943-1944	:	_	_	
8-24	1945-1946	1	_	_	
8-25	1946-1947	-	_	_	
8-26	1947-1950	SEQ	_	_	
8-27	1951-1953	ID	_	_	
8-28	1954-1956	NO	_	_	
8-29	1956-1957	:	_	_	
8-30	1958-1962	7171	_	_	
8-31	1963-1965	or	_	_	
8-32	1966-1987	sequence-conservative	_	_	
8-33	1988-1990	or	_	_	
8-34	1991-2012	function-conservative	_	_	
8-35	2013-2021	variants	_	_	
8-36	2022-2029	thereof	_	_	
8-37	2029-2030	,	_	_	
8-38	2031-2033	or	_	_	
8-39	2034-2041	against	_	_	
8-40	2042-2043	a	_	_	
8-41	2044-2055	polypeptide	_	_	
8-42	2056-2064	sequence	_	_	
8-43	2065-2074	contained	_	_	
8-44	2075-2077	in	_	_	
8-45	2078-2081	any	_	_	
8-46	2082-2084	of	_	_	
8-47	2085-2088	SEQ	_	_	
8-48	2089-2091	ID	_	_	
8-49	2092-2094	NO	_	_	
8-50	2094-2095	:	_	_	
8-51	2096-2100	7172	_	_	
8-52	2100-2101	-	_	_	
8-53	2101-2104	SEQ	_	_	
8-54	2105-2107	ID	_	_	
8-55	2108-2110	NO	_	_	
8-56	2110-2111	:	_	_	
8-57	2112-2117	14342	_	_	
8-58	2118-2120	or	_	_	
8-59	2121-2142	function-conservative	_	_	
8-60	2143-2151	variants	_	_	
8-61	2152-2159	thereof	_	_	
8-62	2159-2160	.	_	_	

#Text=In yet another aspect, the invention provides a method for detecting antibacterial-specific antibodies in a sample, which comprises: (i) contacting a sample suspected to contain antibacterial-specific antibodies with an K. pneumoniae antigenic component, under conditions in which a stable antigen-antibody complex can form between the K. pneumoniae antigenic component and antibacterial antibodies in the sample; and (ii) detecting any antigen-antibody complex formed in step (i), wherein detection of an antigen-antibody complex indicates the presence of antibacterial antibodies in the sample.
9-1	2161-2163	In	_	_	
9-2	2164-2167	yet	_	_	
9-3	2168-2175	another	_	_	
9-4	2176-2182	aspect	_	_	
9-5	2182-2183	,	_	_	
9-6	2184-2187	the	_	_	
9-7	2188-2197	invention	_	_	
9-8	2198-2206	provides	_	_	
9-9	2207-2208	a	*[1]	10-5[2_1]	
9-10	2209-2215	method	*[1]	_	
9-11	2216-2219	for	*[1]	_	
9-12	2220-2229	detecting	*[1]	_	
9-13	2230-2252	antibacterial-specific	*[1]	_	
9-14	2253-2263	antibodies	*[1]	_	
9-15	2264-2266	in	_	_	
9-16	2267-2268	a	_	_	
9-17	2269-2275	sample	_	_	
9-18	2275-2276	,	_	_	
9-19	2277-2282	which	_	_	
9-20	2283-2292	comprises	_	_	
9-21	2292-2293	:	_	_	
9-22	2294-2295	(	_	_	
9-23	2295-2296	i	_	_	
9-24	2296-2297	)	_	_	
9-25	2298-2308	contacting	_	_	
9-26	2309-2310	a	_	_	
9-27	2311-2317	sample	_	_	
9-28	2318-2327	suspected	_	_	
9-29	2328-2330	to	_	_	
9-30	2331-2338	contain	_	_	
9-31	2339-2361	antibacterial-specific	_	_	
9-32	2362-2372	antibodies	_	_	
9-33	2373-2377	with	_	_	
9-34	2378-2380	an	_	_	
9-35	2381-2382	K	_	_	
9-36	2382-2383	.	_	_	
9-37	2384-2394	pneumoniae	_	_	
9-38	2395-2404	antigenic	_	_	
9-39	2405-2414	component	_	_	
9-40	2414-2415	,	_	_	
9-41	2416-2421	under	_	_	
9-42	2422-2432	conditions	_	_	
9-43	2433-2435	in	_	_	
9-44	2436-2441	which	_	_	
9-45	2442-2443	a	_	_	
9-46	2444-2450	stable	_	_	
9-47	2451-2467	antigen-antibody	_	_	
9-48	2468-2475	complex	_	_	
9-49	2476-2479	can	_	_	
9-50	2480-2484	form	_	_	
9-51	2485-2492	between	_	_	
9-52	2493-2496	the	_	_	
9-53	2497-2498	K	_	_	
9-54	2498-2499	.	_	_	
9-55	2500-2510	pneumoniae	_	_	
9-56	2511-2520	antigenic	_	_	
9-57	2521-2530	component	_	_	
9-58	2531-2534	and	_	_	
9-59	2535-2548	antibacterial	_	_	
9-60	2549-2559	antibodies	_	_	
9-61	2560-2562	in	_	_	
9-62	2563-2566	the	_	_	
9-63	2567-2573	sample	_	_	
9-64	2573-2574	;	_	_	
9-65	2575-2578	and	_	_	
9-66	2579-2580	(	_	_	
9-67	2580-2582	ii	_	_	
9-68	2582-2583	)	_	_	
9-69	2584-2593	detecting	_	_	
9-70	2594-2597	any	_	_	
9-71	2598-2614	antigen-antibody	_	_	
9-72	2615-2622	complex	_	_	
9-73	2623-2629	formed	_	_	
9-74	2630-2632	in	_	_	
9-75	2633-2637	step	_	_	
9-76	2638-2639	(	_	_	
9-77	2639-2640	i	_	_	
9-78	2640-2641	)	_	_	
9-79	2641-2642	,	_	_	
9-80	2643-2650	wherein	_	_	
9-81	2651-2660	detection	_	_	
9-82	2661-2663	of	_	_	
9-83	2664-2666	an	_	_	
9-84	2667-2683	antigen-antibody	_	_	
9-85	2684-2691	complex	_	_	
9-86	2692-2701	indicates	_	_	
9-87	2702-2705	the	_	_	
9-88	2706-2714	presence	_	_	
9-89	2715-2717	of	_	_	
9-90	2718-2731	antibacterial	_	_	
9-91	2732-2742	antibodies	_	_	
9-92	2743-2745	in	_	_	
9-93	2746-2749	the	_	_	
9-94	2750-2756	sample	_	_	
9-95	2756-2757	.	_	_	

#Text=In different embodiments of this method, the antigenic component is encoded by a sequence contained in any of SEQ ID NO: 1-SEQ ID NO: 7171 or sequence-conservative and function-conservative variants thereof, or is a polypeptide sequence contained in any of SEQ ID NO: 7172-SEQ ID NO: 14342 or function-conservative variants thereof.
10-1	2758-2760	In	_	_	
10-2	2761-2770	different	_	_	
10-3	2771-2782	embodiments	_	_	
10-4	2783-2785	of	_	_	
10-5	2786-2790	this	*[2]	_	
10-6	2791-2797	method	*[2]	_	
10-7	2797-2798	,	_	_	
10-8	2799-2802	the	_	_	
10-9	2803-2812	antigenic	_	_	
10-10	2813-2822	component	_	_	
10-11	2823-2825	is	_	_	
10-12	2826-2833	encoded	_	_	
10-13	2834-2836	by	_	_	
10-14	2837-2838	a	_	_	
10-15	2839-2847	sequence	_	_	
10-16	2848-2857	contained	_	_	
10-17	2858-2860	in	_	_	
10-18	2861-2864	any	_	_	
10-19	2865-2867	of	_	_	
10-20	2868-2871	SEQ	_	_	
10-21	2872-2874	ID	_	_	
10-22	2875-2877	NO	_	_	
10-23	2877-2878	:	_	_	
10-24	2879-2880	1	_	_	
10-25	2880-2881	-	_	_	
10-26	2881-2884	SEQ	_	_	
10-27	2885-2887	ID	_	_	
10-28	2888-2890	NO	_	_	
10-29	2890-2891	:	_	_	
10-30	2892-2896	7171	_	_	
10-31	2897-2899	or	_	_	
10-32	2900-2921	sequence-conservative	_	_	
10-33	2922-2925	and	_	_	
10-34	2926-2947	function-conservative	_	_	
10-35	2948-2956	variants	_	_	
10-36	2957-2964	thereof	_	_	
10-37	2964-2965	,	_	_	
10-38	2966-2968	or	_	_	
10-39	2969-2971	is	_	_	
10-40	2972-2973	a	_	_	
10-41	2974-2985	polypeptide	_	_	
10-42	2986-2994	sequence	_	_	
10-43	2995-3004	contained	_	_	
10-44	3005-3007	in	_	_	
10-45	3008-3011	any	_	_	
10-46	3012-3014	of	_	_	
10-47	3015-3018	SEQ	_	_	
10-48	3019-3021	ID	_	_	
10-49	3022-3024	NO	_	_	
10-50	3024-3025	:	_	_	
10-51	3026-3030	7172	_	_	
10-52	3030-3031	-	_	_	
10-53	3031-3034	SEQ	_	_	
10-54	3035-3037	ID	_	_	
10-55	3038-3040	NO	_	_	
10-56	3040-3041	:	_	_	
10-57	3042-3047	14342	_	_	
10-58	3048-3050	or	_	_	
10-59	3051-3072	function-conservative	_	_	
10-60	3073-3081	variants	_	_	
10-61	3082-3089	thereof	_	_	
10-62	3089-3090	.	_	_	

#Text=In another aspect, the invention features a method of generating vaccines for immunizing an individual against K. pneumoniae.
11-1	3091-3093	In	_	_	
11-2	3094-3101	another	_	_	
11-3	3102-3108	aspect	_	_	
11-4	3108-3109	,	_	_	
11-5	3110-3113	the	_	_	
11-6	3114-3123	invention	_	_	
11-7	3124-3132	features	_	_	
11-8	3133-3134	a	_	_	
11-9	3135-3141	method	_	_	
11-10	3142-3144	of	_	_	
11-11	3145-3155	generating	_	_	
11-12	3156-3164	vaccines	_	_	
11-13	3165-3168	for	_	_	
11-14	3169-3179	immunizing	_	_	
11-15	3180-3182	an	_	_	
11-16	3183-3193	individual	_	_	
11-17	3194-3201	against	_	_	
11-18	3202-3203	K	_	_	
11-19	3203-3204	.	_	_	
11-20	3205-3215	pneumoniae	_	_	
11-21	3215-3216	.	_	_	

#Text=The method includes: immunizing a subject with an K. pneumoniae polypeptide, e.g., a surface or secreted polypeptide, or a combination of such peptides or active portion(s) thereof, and a pharmaceutically acceptable carrier.
12-1	3217-3220	The	_	_	
12-2	3221-3227	method	_	_	
12-3	3228-3236	includes	_	_	
12-4	3236-3237	:	_	_	
12-5	3238-3248	immunizing	_	_	
12-6	3249-3250	a	_	_	
12-7	3251-3258	subject	_	_	
12-8	3259-3263	with	_	_	
12-9	3264-3266	an	_	_	
12-10	3267-3268	K	_	_	
12-11	3268-3269	.	_	_	
12-12	3270-3280	pneumoniae	_	_	
12-13	3281-3292	polypeptide	_	_	
12-14	3292-3293	,	_	_	
12-15	3294-3297	e.g	_	_	
12-16	3297-3298	.	_	_	
12-17	3298-3299	,	_	_	
12-18	3300-3301	a	_	_	
12-19	3302-3309	surface	_	_	
12-20	3310-3312	or	_	_	
12-21	3313-3321	secreted	_	_	
12-22	3322-3333	polypeptide	_	_	
12-23	3333-3334	,	_	_	
12-24	3335-3337	or	_	_	
12-25	3338-3339	a	_	_	
12-26	3340-3351	combination	_	_	
12-27	3352-3354	of	_	_	
12-28	3355-3359	such	_	_	
12-29	3360-3368	peptides	_	_	
12-30	3369-3371	or	_	_	
12-31	3372-3378	active	_	_	
12-32	3379-3386	portion	_	_	
12-33	3386-3387	(	_	_	
12-34	3387-3388	s	_	_	
12-35	3388-3389	)	_	_	
12-36	3390-3397	thereof	_	_	
12-37	3397-3398	,	_	_	
12-38	3399-3402	and	_	_	
12-39	3403-3404	a	_	_	
12-40	3405-3421	pharmaceutically	_	_	
12-41	3422-3432	acceptable	_	_	
12-42	3433-3440	carrier	_	_	
12-43	3440-3441	.	_	_	

#Text=Such vaccines have therapeutic and prophylactic utilities.
13-1	3442-3446	Such	_	_	
13-2	3447-3455	vaccines	_	_	
13-3	3456-3460	have	_	_	
13-4	3461-3472	therapeutic	_	_	
13-5	3473-3476	and	_	_	
13-6	3477-3489	prophylactic	_	_	
13-7	3490-3499	utilities	_	_	
13-8	3499-3500	.	_	_	

#Text=In another aspect, the invention features a method of evaluating a compound, e.g., a polypeptide, e.g., a fragment of a host cell polypeptide, for the ability to bind an K. pneumoniae polypeptide.
14-1	3501-3503	In	_	_	
14-2	3504-3511	another	_	_	
14-3	3512-3518	aspect	_	_	
14-4	3518-3519	,	_	_	
14-5	3520-3523	the	_	_	
14-6	3524-3533	invention	_	_	
14-7	3534-3542	features	_	_	
14-8	3543-3544	a	_	_	
14-9	3545-3551	method	_	_	
14-10	3552-3554	of	_	_	
14-11	3555-3565	evaluating	_	_	
14-12	3566-3567	a	_	_	
14-13	3568-3576	compound	_	_	
14-14	3576-3577	,	_	_	
14-15	3578-3581	e.g	_	_	
14-16	3581-3582	.	_	_	
14-17	3582-3583	,	_	_	
14-18	3584-3585	a	_	_	
14-19	3586-3597	polypeptide	_	_	
14-20	3597-3598	,	_	_	
14-21	3599-3602	e.g	_	_	
14-22	3602-3603	.	_	_	
14-23	3603-3604	,	_	_	
14-24	3605-3606	a	_	_	
14-25	3607-3615	fragment	_	_	
14-26	3616-3618	of	_	_	
14-27	3619-3620	a	_	_	
14-28	3621-3625	host	_	_	
14-29	3626-3630	cell	_	_	
14-30	3631-3642	polypeptide	_	_	
14-31	3642-3643	,	_	_	
14-32	3644-3647	for	_	_	
14-33	3648-3651	the	_	_	
14-34	3652-3659	ability	_	_	
14-35	3660-3662	to	_	_	
14-36	3663-3667	bind	_	_	
14-37	3668-3670	an	_	_	
14-38	3671-3672	K	_	_	
14-39	3672-3673	.	_	_	
14-40	3674-3684	pneumoniae	_	_	
14-41	3685-3696	polypeptide	_	_	
14-42	3696-3697	.	_	_	

#Text=The method includes contacting the compound to be evaluated with an K. pneumoniae polypeptide and determining if the compound binds or otherwise interacts with the K. pneumoniae polypeptide.
15-1	3698-3701	The	_	_	
15-2	3702-3708	method	_	_	
15-3	3709-3717	includes	_	_	
15-4	3718-3728	contacting	_	_	
15-5	3729-3732	the	_	_	
15-6	3733-3741	compound	_	_	
15-7	3742-3744	to	_	_	
15-8	3745-3747	be	_	_	
15-9	3748-3757	evaluated	_	_	
15-10	3758-3762	with	_	_	
15-11	3763-3765	an	_	_	
15-12	3766-3767	K	_	_	
15-13	3767-3768	.	_	_	
15-14	3769-3779	pneumoniae	_	_	
15-15	3780-3791	polypeptide	_	_	
15-16	3792-3795	and	_	_	
15-17	3796-3807	determining	_	_	
15-18	3808-3810	if	_	_	
15-19	3811-3814	the	_	_	
15-20	3815-3823	compound	_	_	
15-21	3824-3829	binds	_	_	
15-22	3830-3832	or	_	_	
15-23	3833-3842	otherwise	_	_	
15-24	3843-3852	interacts	_	_	
15-25	3853-3857	with	_	_	
15-26	3858-3861	the	_	_	
15-27	3862-3863	K	_	_	
15-28	3863-3864	.	_	_	
15-29	3865-3875	pneumoniae	_	_	
15-30	3876-3887	polypeptide	_	_	
15-31	3887-3888	.	_	_	

#Text=Compounds which bind or otherwise interact with K. pneumoniae polypeptides are candidates as modulators, including activators and inhibitors, of the bacterial life cycle.
16-1	3889-3898	Compounds	_	_	
16-2	3899-3904	which	_	_	
16-3	3905-3909	bind	_	_	
16-4	3910-3912	or	_	_	
16-5	3913-3922	otherwise	_	_	
16-6	3923-3931	interact	_	_	
16-7	3932-3936	with	_	_	
16-8	3937-3938	K	_	_	
16-9	3938-3939	.	_	_	
16-10	3940-3950	pneumoniae	_	_	
16-11	3951-3963	polypeptides	_	_	
16-12	3964-3967	are	_	_	
16-13	3968-3978	candidates	_	_	
16-14	3979-3981	as	_	_	
16-15	3982-3992	modulators	_	_	
16-16	3992-3993	,	_	_	
16-17	3994-4003	including	_	_	
16-18	4004-4014	activators	_	_	
16-19	4015-4018	and	_	_	
16-20	4019-4029	inhibitors	_	_	
16-21	4029-4030	,	_	_	
16-22	4031-4033	of	_	_	
16-23	4034-4037	the	_	_	
16-24	4038-4047	bacterial	_	_	
16-25	4048-4052	life	_	_	
16-26	4053-4058	cycle	_	_	
16-27	4058-4059	.	_	_	

#Text=These assays can be performed in vitro or in vivo.
17-1	4060-4065	These	_	_	
17-2	4066-4072	assays	_	_	
17-3	4073-4076	can	_	_	
17-4	4077-4079	be	_	_	
17-5	4080-4089	performed	_	_	
17-6	4090-4092	in	_	_	
17-7	4093-4098	vitro	_	_	
17-8	4099-4101	or	_	_	
17-9	4102-4104	in	_	_	
17-10	4105-4109	vivo	_	_	
17-11	4109-4110	.	_	_	
